Billionaire hedge fund manager David Tepper, of Appaloosa Management, bought 7.8 million shares of Boston Scientific stock during the 4th quarter, according to regulatory filings, for a stake with a market value of $41.6 million as of Dec. 31.
That could be a sign that rumors of a private equity takeover have some substance, according to TheStreet.com. Appaloosa’s stake in BSX accounts for about 6% of its entire, $765 million portfolio, according to the website. With share prices holding steady at the low price of about $6, Tepper’s interest could signal that the rumors are right.
"Given Tepper’s involvement, we think [a PE takeover] could be the case – making Boston Scientific (NYSE:BSX) a great speculative play. It is priced low enough to be an OK investment in the short term, but if the company is taken over, the returns could be magical," according to The Street.
BSX shares broke the $6 mark today, closing up 5.9% at $6.25 for the day.
OTC lists Titan Medical
Canadian robotic surgery device maker Titan Medical (TSX:TMD) is now listed on the OTC exchange under the symbol "TITXF." Read more
Burrill & Co. opens in Taiwan
Life science investment shop Burrill & Co. plans to open an office in Taiwan led by Dr. Marietta Wu. Read more
MGT Capital plans reverse split to stay on NYSE
MGT Capital Investments (NYSE:MGT) plans to engineer a reverse split of its common stock before March 31in order to come back into compliance with the exchange’s listing rules. Read more
Deals Roundup
- Lantheus Medical Imaging inks Chinese distribution deal
- Revolutions Medical signs distribution agreement with Hectare Systems
- McKesson, Aloka Co., others land DoD contracts
- Orchid Orthopedic Solutions acquires Sandvik’s medical technology business
Analysts’ ups and downs
- 3M Co. (NYSE:MMM): Deutsche Bank downgrades from "buy" to "hold."
- Baxter International (NYSE:BAX): Citigroup upgrades from "sell" to "neutral."
- Cerner (NSDQ:CERN): Morgan Stanley raises price target from $70 to $82, maintains on "overweight" rating.
- Conceptus (NSDQ:CPTS): Zacks Investment Research upgrades from "underperform" to "neutral;" GARP Research reiterates "buy" rating; Barrington Research reiterates "outperform" rating, sets $20 price target; Cantor Fitzgerald initiates coverage at "buy."
- DexCom (NSDQ:DXCM): Canaccord Genuity maintains "buy" rating, raises price target to $11.50 from $11; Wunderlich Securities raises price target to $15.
- Greatbatch (NYSE:BG): Piper Jaffray upgrades to "neutral" from "underweight," raises price target to $25 from $20.
- Integra Lifesciences (NSDQ:IART): Citigroup raises price target to $36, maintains "buy" rating; ThinkEquity initiates coverage with "buy" rating, $37 price target; Argus downgrades from "buy" to "hold;" Jefferies Group reiterates "buy" rating.
- Teleflex (NYSE:TFX): Leerink Swann maintains "market perform" rating, lowers price target from $64 to $63.
- Wright Medical (NSDQ:WMGI): BMO downgrades to "market perform," sets $15 price target.
